Bleeding Disorders Demystified: What Is Haemophilia and Why It Matters

Haemophilia is a rare genetic disorder that affects the blood's ability to clot properly, and, while it's estimated that around 200,000 people worldwide live with it, the real number might be much higher, possibly over 1.1 million. This occurs due to the fact that numerous cases remain undetected.

Haemophilia primarily impacts males, occurring in approximately one out of every 5,000 male newborns. Women can carry the gene and may have mild symptoms, but it's usually men who face the more serious effects. For those living with Haemophilia, unexpected bleeding and joint damage are common struggles that can make everyday life challenging.

The financial burden is just as serious. In the U.S. alone, managing Haemophilia B can cost over $200,000 each year and for severe cases, that number can skyrocket to more than $630,000.

In this article, we’ll explain Haemophilia, its causes, the signs to look out for, and the treatment options available today. We’ll also examine how this condition impacts daily life and the exciting new treatments that could make a real difference for those living with it.

How Haemophilia is Usually Discovered

People find out they have Haemophilia at different points in their lives. This varies according to the severity of their disease. The path to diagnosis might start right after birth or stay hidden until someone reaches adulthood. That's why knowing the warning signs is vital to getting treatment quickly.

Early signs in babies and children

The time it takes to diagnose Haemophilia relates directly to how severe it is. Children with severe Haemophilia often exhibit significant bleeding issues from an early age. The majority receive their diagnoses during their first year. Notably, the median age at diagnosis is just 1 month for severe cases, 8 months for moderate Haemophilia, and 36 months for those with mild forms.

If a baby's family history includes Haemophilia, doctors will test them immediately. Approximately two-thirds of newborns who have Haemophilia have a family history. Testing happens in three main situations:

• Babies born into families with Haemophilia history

• Infants whose mothers are Haemophilia carriers

• Newborns showing unusual bleeding symptoms at birth

Without any family history, which happens in about one-third of cases, doctors usually find Haemophilia after an unusual bleeding event. Baby boys might bleed too much after circumcision. They might also bleed excessively from simple procedures like heel sticks or blood draws. The condition becomes easier to spot once children start moving around. Parents often notice strange bruising when their child starts crawling or standing. More obvious symptoms show up between 12 and 18 months as kids become more active and bruising stands out more.Blood tests assess how long it takes for blood to clot and measure levels of factors VIII and IX. Joint bleeding (hemarthrosis) is one of the most important warning signs in children. The bleeding follows a pattern:

1. The joint feels tight, but looks normal

2. It becomes swollen, hot, and hurts when bent

3. More swelling appears as bleeding continues

4. Stiff joints and painful during movements

When adults get diagnosed later in life

Milder forms of Haemophilia might not show up until adulthood. People with factor levels above 5% usually bleed too much only after major injuries, big surgeries, or dental work. Adults often learn about their Haemophilia during lab tests before surgery or after bleeding too much during a medical procedure. This explains why mild cases can go unnoticed for decades. Some people first learn about their condition during routine medical work.

Acquired Haemophilia offers another path to diagnosis, especially in older adults. Unlike inherited Haemophilia, this type develops later in life and affects about 0.2–1 person per million each year. This autoimmune condition shows up mostly in people over 60, affecting about 80% of cases.

Diagnosing acquired Haemophilia is tough because

• Most patients typically do not have a prior history of bleeding issues.

• Severe bleeding can start suddenly

• Lab tests are complicated

Some groups need extra attention for acquired Haemophilia. This includes elderly patients and women who have just given birth who suddenly start bleeding abnormally. However, nearly 50% of individuals with acquired Haemophilia have no identifiable cause.

Finding Haemophilia early is vital. Quick diagnosis helps manage the condition better and prevents life-threatening problems. Understanding these different ways Haemophilia appears helps families and healthcare providers spot it sooner, whatever the timing of first symptoms.

Understanding the Root Causes

Our genetic code, specifically the chromosomes determining biological sex, holds the mechanisms behind Haemophilia. These genetic mechanisms help explain why some people face severe symptoms while others experience milder forms of the condition.

Genetic inheritance and X-linked pattern

Mutations in genes that give instructions to make blood-clotting proteins cause Haemophilia. The two main types—Haemophilia A and B—come from different genetic problems but follow the same inheritance pattern. Both disorders are inherited as X-linked recessive traits, with the faulty genes situated on the X chromosome. Haemophilia is far less common in females than in males. Males inherit just one X chromosome (XY); hence, a single faulty gene causes Haemophilia. Females have two X chromosomes (XX), and they need mutations in both copies to develop the full condition.

Mutations in the F8 gene that produce clotting factor VIII cause Haemophilia A. The F9 gene mutations, which affect clotting factor IX production, result in Haemophilia B. These genetic changes don't produce enough of these vital clotting proteins. Each son of a mother carrying the Haemophilia gene has a 50% chance of inheriting the condition. Her daughters face the same odds of becoming carriers. A father with Haemophilia can't pass the condition to his sons, but his daughters will always become carriers. Severe Haemophilia rarely affects females because their second X chromosome usually contains a working gene copy. Notwithstanding that, some female carriers show bleeding symptoms due to a process called X-inactivation or lyonization. Random inactivation of one X chromosome happens in each cell during early fetal development. Female carriers might experience bleeding symptoms if more cells inactivate the X chromosome with the normal gene.

When Haemophilia is not inherited

Family inheritance doesn't explain all Haemophilia cases. Spontaneous mutations cause about one-third of all Haemophilia A and B cases with no family history. These de novo mutations stem from DNA replication errors during sperm or egg cell development.

People sometimes develop Haemophilia later in life through a different process. This condition, called acquired Haemophilia, happens when the immune system attacks clotting factors, especially factor VIII. Such Haemophilia is acquired and is distinct from inherited Haemophilia in multiple aspects:

• Both men and women get it equally

• It affects about 0.2-1 person per million each year

• Most cases appear in older adults aged 60-80 years

• Pregnant women might develop it after giving birth

Scientists can identify the mechanisms in only half of acquired Haemophilia cases. The remaining cases are considered idiopathic, meaning they occur without a known or identifiable cause. Known causes include:

• Autoimmune disorders (17-18% of cases)

• Cancer and blood disorders

• Pregnancy (8.4% of cases)

• Reactions to certain medications

The genetic foundations of Haemophilia explain why treatments must target specific missing clotting factors. This knowledge has guided the development of targeted therapies and supports current research into potential genetic cures.

Living with Haemophilia: Daily Challenges

Living with Haemophilia brings challenges that extend beyond its genetic roots. People with this bleeding disorder need to plan their daily activities carefully to avoid serious complications.

Managing joint pain and internal bleeding

70% to 80% of Haemophilia patients experience joint hemorrhage, often known as hemarthrosis. All of this represents one of their greatest everyday problems. Blood that enters a joint space triggers pain and inflammation in a specific pattern. Patients first feel tightness, then swelling and heat. Pain follows, and they lose some movement.

If not controlled appropriately, repeated bleeding can cause lasting joint injury. This creates an ongoing cycle of pain and disability. More than half of Haemophilia patients say their painful joints limit what they can do each day. Research shows that 89% of patients can't do everyday activities easily. About 85% say ongoing joint pain affects their mood negatively.

The PRICE approach helps protect against joint bleeds:

• Protection: Use splints or braces, especially for target joints

• Rest: Limit weight-bearing on affected joints

• Ice: Administer for ten to twenty minutes each 1-2 hours.

• Compression: Use elastic bandages from the lowest point upward

• Positioning: Maintain the part of the body affected above the heart level.

Physical therapy is vital for joint health because it builds stronger muscles that support joints better. Habitual exercise has been demonstrated to help prevent spontaneous bleeding. Starting movement again after a bleed helps to reduce stiffness in the joints and "joint freeze."

Activities and medications to avoid

Physical exercise is vital for Haemophilia patients; however, not every activity is equally safe. The National Haemophilia Foundation organizes programs by risk level:

• Safe activities: Swimming, hiking, and aquatics

• Moderate risk: Bowling, tennis

• High risk/not recommended: Football, hockey, boxing, rugby

Timing factor replacement therapy correctly before physical activities makes a big difference. People on prophylaxis should match their gym schedule with clotting factor infusions. They typically take treatment in the morning for daytime activities or in the late afternoon for evening exercise.

Some drugs increase bleeding risk by a lot and should be avoided:

• Aspirin and aspirin-containing products (Alka-Seltzer, Excedrin)

• Non-steroidal anti-inflammatory drugs (ibuprofen, naproxen)

• Blood thinners (warfarin, heparin)

• Some antibiotics (particularly cephalosporins)

• Certain herbal supplements (ginkgo biloba, large amounts of garlic)

Acetaminophen (Tylenol) works better for pain management than NSAIDs. Doctors might prescribe low-dose opioids for severe pain under close supervision.

Regular visits to a detailed Haemophilia treatment centre (HTC) are vital. Studies show that such patients have fewer bleeding problems and hospital stays. The centers' team-based approach helps patients live better lives.

Treatment Options and What to Expect

Haemophilia treatment has transformed over the decades. Patients now have options that range from standard replacement therapies to advanced genetic approaches. Quality of life keeps improving for people with bleeding disorders thanks to medical breakthroughs.

Factor replacement and non-factor therapies

Replacing missing clotting factors through intravenous infusions remains the standard treatment for Haemophilia. Two main forms of these treatments exist:

Plasma-derived factors come from human blood donations that go through purification processes to remove viruses. Recombinant factors, which got approval in 1992, use DNA technology without human plasma and eliminate bloodborne infection risks.

Doctors can administer factor replacement in two ways:

• Prophylactic treatment: Regularly scheduled infusions to prevent bleeding

• On-demand treatment: Infusions given after bleeding begins

Standard factor VIII has a fairly brief half-life (10-12 hours), whereas factor IX persists for around 16-18 hours. Patients need multiple weekly infusions as a result, which creates a heavy treatment burden. Extended half-life products have emerged that allow less frequent dosing. These modified factors can reduce injection frequency to once weekly or biweekly and maintain higher factor levels.

Innovative non-factor therapies now give patients more choices. Emicizumab (Hemlibra®) works as a bispecific antibody that mimics factor VIII's function when it binds to factors IXa and X. Patients can receive it subcutaneously instead of intravenously, either weekly, biweekly, or monthly. This treatment has shown impressive results for Haemophilia A patient with inhibitors who had limited options before - 63-87% of patients experienced no treated bleeds.

What Gene therapy mean for the future

Gene therapy stands out as one of the most exciting developments. This breakthrough could provide a one-time treatment that might eliminate the need for ongoing infusions. The treatment delivers functional copies of the missing factor gene to liver cells through a modified virus carrier (adeno-associated virus or AAV). These genes tell the body to produce its own clotting factors once they reach liver cells.

The FDA approved gene therapies for both types of Haemophilia. Hemgenix® for Haemophilia B got approval in November 2022, and Roctavian® for severe Haemophilia A followed in June 2023. Many patients saw their bleeding episodes drop substantially after gene therapy - a newer study showed a 71% average reduction in bleed rate compared to the previous year.

Gene therapy isn't right for everyone. Some patients can't receive treatment because they have antibodies to the viral vector. Others require immunosuppressive drugs to avoid liver inflammation. This approach still gives many patients hope for a "Haemophilia-free state of mind" they've always wanted.

Coping, Support, and Long-Term Outlook

Owing to improved therapies, individuals with Haemophilia are now living full and active lives. Patients who get competent care have life expectancies comparable to the rest of the population. Patients with mild Haemophilia are expected to live almost as long as the general population.

How to stay active and safe

Consistent workout is a critical aspect of maintaining joint health if you have Haemophilia. Research shows exercise helps reduce unexpected bleeding and builds muscles that protect vulnerable joints. You should always check with your Haemophilia care team before starting any exercise routine.

Low-impact activities provide great benefits without much risk. Swimming stands out as one of the best choices because water creates gentle resistance that doesn't strain your joints. Here are other good options:

• Walking and stationary biking

• Golf and bowling

• Swimming and aquatics

The timing of your factor replacement therapy plays a big role in staying active. The best approach is to match your gym schedule with clotting factor infusions. Most people take their treatment in the morning if they plan daytime activities.

Of course, you should avoid high-risk sports, especially contact sports like football, hockey, rugby, and boxing. When doing moderate-risk activities, protective gear such as braces and splints can help keep vulnerable joints safe.

Support systems and treatment centers

Haemophilia Treatment Centers provide the foundation of comprehensive therapy. These specialist institutions gather up hematologists, nurses, physical therapists, social workers, and various other healthcare professionals. According to studies, patients at HTCs experience fewer problems and hospitalizations. Meeting others who understand Haemophilia's challenges can reshape the scene. Groups like the Haemophilia Federation of America, the National Haemophilia Foundation, and the World Federation of Haemophilia are great ways to get resources. They provide education, advocacy, emergency help, and scholarships.

To name just one example, see how local chapters run regular support groups where children and adults meet others with Haemophilia. Programs like Blood Brotherhood and Blood Sisterhood help adult men and women share experiences and find support.

Many financial assistance programs help cover treatment costs. These resources, combined with early diagnosis and effective therapy, help people with Haemophilia lead active, rewarding lives despite their condition's challenges.

Conclusion

Medical advances have changed Haemophilia from a debilitating condition to a manageable disorder. People with Haemophilia now lead active lives that meet their goals, thanks to modern treatments and complete care systems. Gene therapy has emerged as a breakthrough development. It offers hope that regular factor infusions might become optional instead of necessary in the future. The successful management of Haemophilia relies on early diagnosis, proper treatment, and strong support networks.

Haemophilia patients' outlook keeps getting better. Patients who receive appropriate care can expect to live as long as anyone else. Individuals having Haemophilia can participate in the majority of daily activities because to specialist treatment facilities, peer support networks, and cautious activity planning.

Note that each person's experience with Haemophilia is different. A treatment that works for one patient might not work for others. The best health outcomes depend on regular contact with healthcare providers and staying updated about new treatments.